Insulet Corporation $PODD Shares Sold by Munich Reinsurance Co Stock Corp in Munich

Munich Reinsurance Co Stock Corp in Munich lowered its position in shares of Insulet Corporation (NASDAQ:PODD) by 20.4% in the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 16,084 shares of the medical instruments supplier’s stock after selling 4,134 shares during the quarter. Munich Reinsurance Co Stock Corp in Munich’s holdings in Insulet were worth $3,375,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also made changes to their positions in the company. Nordea Investment Management AB lifted its stake in shares of Insulet by 35.0% in the fourth quarter. Nordea Investment Management AB now owns 551,133 shares of the medical instruments supplier’s stock worth $157,128,000 after buying an additional 142,922 shares in the last quarter. Jain Global LLC grew its stake in Insulet by 148.2% during the 3rd quarter. Jain Global LLC now owns 106,710 shares of the medical instruments supplier’s stock valued at $32,945,000 after acquiring an additional 63,719 shares in the last quarter. Mitsubishi UFJ Trust & Banking Corp grew its stake in Insulet by 26.5% during the 4th quarter. Mitsubishi UFJ Trust & Banking Corp now owns 43,921 shares of the medical instruments supplier’s stock valued at $12,484,000 after acquiring an additional 9,206 shares in the last quarter. Zevenbergen Capital Investments LLC acquired a new stake in Insulet in the 4th quarter valued at about $32,143,000. Finally, Aberdeen Group plc raised its holdings in Insulet by 45.6% in the 4th quarter. Aberdeen Group plc now owns 225,429 shares of the medical instruments supplier’s stock valued at $64,076,000 after acquiring an additional 70,607 shares during the last quarter.

Insider Buying and Selling

In related news, Director Timothy C. Stonesifer purchased 2,790 shares of the business’s stock in a transaction on Wednesday, June 3rd. The shares were bought at an average price of $143.51 per share, for a total transaction of $400,392.90. Following the acquisition, the director directly owned 9,041 shares in the company, valued at $1,297,473.91. This trade represents a 44.63% increase in their ownership of the stock. The acquisition was disclosed in a document filed with the SEC, which can be accessed through the SEC website. 0.36% of the stock is owned by insiders.

Insulet Stock Performance

Shares of Insulet stock opened at $157.46 on Thursday. The stock has a market capitalization of $10.91 billion, a price-to-earnings ratio of 36.62, a price-to-earnings-growth ratio of 1.13 and a beta of 1.11. Insulet Corporation has a 12 month low of $138.79 and a 12 month high of $354.88. The company has a debt-to-equity ratio of 0.71, a current ratio of 2.49 and a quick ratio of 1.81. The business has a 50-day moving average of $153.40 and a 200 day moving average of $212.61.

Insulet (NASDAQ:PODD) last posted its quarterly earnings data on Wednesday, May 6th. The medical instruments supplier reported $1.42 EPS for the quarter, beating the consensus estimate of $1.19 by $0.23. The business had revenue of $761.70 million during the quarter, compared to analyst estimates of $729.89 million. Insulet had a net margin of 10.44% and a return on equity of 26.87%. The business’s revenue for the quarter was up 33.9% compared to the same quarter last year. During the same quarter last year, the firm posted $1.02 earnings per share. Insulet has set its FY 2026 guidance at 6.210- EPS. As a group, sell-side analysts forecast that Insulet Corporation will post 6.46 earnings per share for the current year.

Analysts Set New Price Targets

Several brokerages have recently weighed in on PODD. Rothschild & Co Redburn restated a “neutral” rating and set a $220.00 target price (down from $380.00) on shares of Insulet in a report on Friday, April 24th. JPMorgan Chase & Co. cut their price target on Insulet from $340.00 to $275.00 and set an “overweight” rating for the company in a report on Thursday, May 7th. Royal Bank Of Canada reiterated an “outperform” rating and set a $280.00 price objective on shares of Insulet in a research report on Wednesday, May 27th. William Blair began coverage on Insulet in a research note on Wednesday, May 20th. They set an “outperform” rating on the stock. Finally, BTIG Research dropped their target price on Insulet from $260.00 to $235.00 and set a “buy” rating for the company in a report on Tuesday, May 26th. Twenty-two analysts have rated the stock with a Buy rating, four have assigned a Hold rating and two have issued a Sell rating to the stock. According to data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average price target of $238.12.

Trending Headlines about Insulet

Here are the key news stories impacting Insulet this week:

• Positive Sentiment: Insulet launched Omnipod 5 in Spain, expanding its commercial footprint to a 20th country and adding Omnipod Discover to support digital diabetes care. Article: Insulet Broadens Omnipod 5 Presence With Commercial Launch in Spain
• Neutral Sentiment: Several analyst and commentary pieces noted Insulet’s growth potential from Omnipod 5 and its history of earnings beats, though they also flagged competition and margin pressures. Article: Is it Prudent to Retain Insulet Stock in Your Portfolio for Now?
• Negative Sentiment: A new class action and multiple follow-up investor alerts accuse Insulet of making misleading statements about manufacturing quality and undisclosed production problems that allegedly led to medical device corrections affecting millions of pods. Article: Levi & Korsinsky Reminds Insulet Corporation Investors of the Pending Class Action Lawsuit
• Negative Sentiment: Additional law firms filed or publicized securities-fraud claims against Insulet, keeping legal risk in focus and likely weighing on sentiment. Article: Pomerantz Law Firm Announces the Filing of a Class Action Against Insulet Corporation and Certain Officers
• Negative Sentiment: More investor notices reminded shareholders of the August 31 deadline to join or lead the lawsuit, signaling that the litigation story is still developing. Article: Deadline Approaching: Insulet Corporation Shareholders Who Lost Money Urged To Contact Law Offices of Howard G. Smith

About Insulet

Insulet Corporation is a medical device company headquartered in Acton, Massachusetts, that develops, manufactures and sells insulin-delivery systems for people with diabetes. The company’s core business is the design and commercialization of its Omnipod family of tubeless, wearable insulin pumps and the consumable Pods that deliver insulin. Insulet’s products aim to simplify insulin delivery for people with type 1 diabetes and insulin-requiring type 2 diabetes by offering an alternative to traditional insulin pens and tethered pump systems.

The company’s product portfolio includes the Omnipod System line—disposable, waterproof Pods that adhere to the skin and deliver insulin—and the associated controllers and mobile applications used to program and monitor insulin delivery.